AMRX
Amneal Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+80/100
Last price
20.30
▼ 0.05 (0.27%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
20.35
Day high
20.60
Day low
20.00
Volume
3.59M
Market cap
$7.07B
P/E (TTM)
41.42
52W range
9.56 – 21.18
Trailing performance
Returnvs SPY
1W
+0.47%
-1.5%
1M
+16.37%
+15.2%
3M
+19.66%
+15.1%
6M
+64.73%
+46.5%
YTD
+61.07%
+46.8%
1Y
+95.33%
+78.9%
3Y
+380.92%
+298.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AMRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+25.94M
Net buying
Buy transactions
17
26.39M shares
Sell transactions
4
447.83K shares
Net transactions
+21
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
166.38M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 17, 26 | BUCHI J. KEVIN Director |
STOCK | 20.45K | $0 | Direct |
| Sep 11, 26 | BUCHI J. KEVIN Director |
CONVERSION | 20.45K | $295.43K | Direct |
| Sep 1, 26 | BOYER ANDREW S Officer |
STOCK | 80.00K | $0 | Direct |
| Aug 21, 26 | BOYER ANDREW S Officer |
STOCK | 152.43K | $0 | Direct |
| Aug 13, 26 | KIELY JOHN J. Director |
SELL | 50.00K | $882.00K | Direct |
| Aug 13, 26 | KIELY JOHN J. Director |
STOCK | 10.00K | $0 | Direct |
| Aug 12, 26 | SHAH NIKITA Officer |
SELL | 146.40K | $2.56M | Direct |
| Aug 12, 26 | DALY JASON B. Officer |
SELL | 216.61K | $3.77M | Direct |
| Aug 10, 26 | PATEL CHIRAG K Chief Executive Officer |
STOCK | 6.38M | $0 | Indirect |
| Aug 10, 26 | PATEL GAUTAM Director |
STOCK | 283.63K | $0 | Indirect |
| Aug 10, 26 | PATEL CHINTU Chief Executive Officer |
STOCK | 6.38M | $0 | Indirect |
| Aug 10, 26 | PATEL TUSHAR BHIKHUBHAI Beneficial Owner of more than 10% of a Class of Security |
STOCK | 12.76M | $0 | Indirect |
| May 11, 26 | AUTOR DEBORAH M Director |
SELL | 34.82K | $450.56K | Direct |
| May 7, 26 | NARK THEODORE C. Director |
— | 34.82K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
GEORGE JEFFREY P. |
Director | 344.61K | Conversion of Exercise of derivative security |
KONIDARIS TASOS |
Chief Financial Officer | 449.43K | Conversion of Exercise of derivative security |
MEISTER PAUL M |
Director | 832.80K | Conversion of Exercise of derivative security |
NARK THEODORE C. |
Director | 325.85K | Conversion of Exercise of derivative security |
PATEL CHINTU |
Chief Executive Officer | — | Stock Award(Grant) |
PATEL CHIRAG K |
Chief Executive Officer | — | Stock Award(Grant) |
PATEL GAUTAM |
Director | — | Stock Award(Grant) |
PATEL TUSHAR BHIKHUBHAI |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
SHAH NIKITA |
Officer | 253.39K | Sale |
YANAI SHLOMO |
Director | 320.80K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$7.07B
Enterprise value$9.23B
Revenue (TTM)$3.12B
Gross profit$1.24B
EBITDA$689.44M
Net income$157.36M
EPS (TTM)$0.49
Free cash flow$-115.33M
Total cash$131.41M
Total debt$2.79B
Book value / share$0.10
Shares outstanding348.30M
Float197.33M
Short % of float4.60%
Dividend yield0.00%
Beta (5Y)1.22
Valuation & profitability ratios
Trailing P/E41.42
Forward P/E17.02
PEG ratio1.93
Price / sales—
Price / book197.04
EV / revenue2.96
EV / EBITDA13.38
Gross margin39.81%
Operating margin18.34%
Profit margin5.05%
Return on equity613.02%
Return on assets8.60%
Debt / equity2,386.53
Current ratio2.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.02B | $2.79B | $2.39B | $2.21B | +8.0% |
| Operating revenue | $3.02B | $2.79B | $2.39B | $2.21B | +8.0% |
| Cost of revenue | $1.91B | $1.77B | $1.57B | $1.43B | +7.4% |
| Gross profit | $1.11B | $1.02B | $820.57M | $784.71M | +9.1% |
| Research & development | $193.81M | $196.56M | $167.78M | $200.05M | -1.4% |
| Selling, general & admin | $526.83M | $476.44M | $429.68M | $399.70M | +10.6% |
| Total operating expense | $715.39M | $672.07M | $581.82M | $595.79M | +6.4% |
| Operating income | $397.91M | $348.37M | $238.75M | $188.92M | +14.2% |
| Net interest income | -$272.46M | -$258.60M | -$251.43M | -$158.67M | -5.4% |
| Pre-tax income | $139.21M | -$55.01M | -$40.27M | -$248.13M | +353.0% |
| Tax provision | $11.28M | $18.86M | $8.45M | $6.66M | -40.2% |
| Net income | $72.06M | -$116.89M | -$83.99M | -$129.99M | +161.6% |
| Net income to common | $72.06M | -$116.89M | -$83.99M | -$129.99M | +161.6% |
| Basic EPS | 0.23 | -0.38 | -0.48 | -0.86 | +160.5% |
| Diluted EPS | 0.22 | -0.38 | -0.48 | -0.86 | +157.9% |
| EBIT | $380.30M | $203.58M | $170.36M | -$89.75M | +86.8% |
| EBITDA | $603.87M | $439.77M | $399.76M | $150.43M | +37.3% |
| Basic shares | 313.37M | 308.98M | 176.14M | 150.94M | +1.4% |
| Diluted shares | 324.81M | 308.98M | 176.14M | 150.94M | +5.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $282.03M | $110.55M | $91.54M | $25.98M | +155.1% |
| Cash & short-term investments | $282.03M | $110.55M | $91.54M | $25.98M | +155.1% |
| Accounts receivable | $895.14M | $775.73M | $613.73M | $741.79M | +15.4% |
| Inventory | $606.30M | $612.45M | $581.38M | $530.74M | -1.0% |
| Total current assets | $1.91B | $1.59B | $1.38B | $1.41B | +20.4% |
| Property, plant & equipment | $550.33M | $523.69M | $550.14M | $589.36M | +5.1% |
| Goodwill & intangibles | $1.16B | $1.33B | $1.49B | $1.69B | -12.8% |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | +5.1% |
| Total current liabilities | $881.63M | $1.13B | $846.60M | $752.80M | -22.0% |
| Current debt | $6.76M | $324.21M | $213.13M | $89.96M | -97.9% |
| Long-term debt | $2.57B | $2.16B | $2.43B | $2.63B | +18.7% |
| Total debt | $2.69B | $2.59B | $2.75B | $2.85B | +3.7% |
| Total liabilities | $3.75B | $3.61B | $3.45B | $3.62B | +3.8% |
| Retained earnings | -$535.00M | -$607.06M | -$490.18M | -$406.18M | +11.9% |
| Shareholder equity | -$70.79M | -$109.27M | $19.78M | $298.42M | +35.2% |
| Working capital | $1.03B | $458.04M | $531.27M | $659.02M | +124.8% |
| Net tangible assets | -$1.23B | -$1.44B | -$1.47B | -$1.40B | +14.5% |
| Shares issued | 314.56M | 309.88M | 306.56M | 151.49M | +1.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $127.93M | -$73.88M | -$48.72M | -$254.79M | +273.2% |
| Depreciation & amortisation | $223.57M | $236.19M | $229.40M | $240.18M | -5.3% |
| Stock-based compensation | $31.95M | $27.77M | $26.82M | $31.85M | +15.1% |
| Change in working capital | -$204.52M | -$4.07M | -$47.19M | -$59.95M | -4,927.4% |
| Operating cash flow | $339.99M | $295.10M | $345.58M | $65.10M | +15.2% |
| Capital expenditure | -$114.36M | -$74.99M | -$69.19M | -$90.59M | -52.5% |
| Investing cash flow | -$112.26M | -$63.00M | -$69.19M | -$174.31M | -78.2% |
| Financing cash flow | -$31.53M | -$211.79M | -$212.57M | -$106.62M | +85.1% |
| Free cash flow | $225.63M | $220.11M | $276.39M | -$25.50M | +2.5% |
| End cash position | $312.94M | $118.42M | $99.11M | $35.23M | +164.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $796.20M | $722.52M | $814.32M | $784.51M | $724.51M | +10.2% |
| Operating revenue | $796.20M | $722.52M | $814.32M | $784.51M | $724.51M | +10.2% |
| Cost of revenue | $461.69M | $402.41M | $517.13M | $510.54M | $438.25M | +14.7% |
| Gross profit | $334.51M | $320.11M | $297.19M | $273.97M | $286.25M | +4.5% |
| Research & development | $41.10M | $39.92M | $36.23M | $65.79M | $49.98M | +3.0% |
| Selling, general & admin | $148.72M | $138.86M | $146.46M | $137.81M | $124.27M | +7.1% |
| Total operating expense | $188.53M | $171.84M | $182.69M | $203.49M | $174.25M | +9.7% |
| Operating income | $145.98M | $148.27M | $114.50M | $70.49M | $112.01M | -1.5% |
| Net interest income | -$55.04M | -$56.87M | -$56.24M | -$94.18M | -$65.10M | +3.2% |
| Pre-tax income | $70.99M | $80.18M | $55.23M | -$5.22M | $51.71M | -11.5% |
| Tax provision | $1.38M | $2.18M | $5.66M | -$23.36M | $16.10M | -36.8% |
| Net income | $57.66M | $62.26M | $35.08M | $2.37M | $22.42M | -7.4% |
| Net income to common | $57.66M | $62.26M | $35.08M | $2.37M | $22.42M | -7.4% |
| Basic EPS | 0.18 | 0.20 | 0.11 | 0.01 | 0.07 | -10.0% |
| Diluted EPS | 0.18 | 0.19 | 0.11 | 0.01 | 0.07 | -5.3% |
| EBIT | $126.03M | $133.54M | $111.47M | $57.59M | $116.81M | -5.6% |
| EBITDA | $173.83M | $176.73M | $160.70M | $111.66M | $176.93M | -1.6% |
| Basic shares | 319.20M | 316.02M | 314.46M | 314.17M | 313.74M | +1.0% |
| Diluted shares | 328.10M | 328.93M | 328.09M | 324.75M | 322.36M | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $127.64M | $197.66M | $282.03M | $201.25M | $71.54M | -35.4% |
| Cash & short-term investments | $127.64M | $197.66M | $282.03M | $201.25M | $71.54M | -35.4% |
| Accounts receivable | $1.02B | $850.86M | $895.14M | $885.20M | $807.64M | +19.9% |
| Inventory | $677.95M | $641.62M | $606.30M | $614.50M | $608.97M | +5.7% |
| Total current assets | $1.95B | $1.80B | $1.91B | $1.84B | $1.58B | +8.3% |
| Property, plant & equipment | $609.92M | $558.76M | $550.33M | $538.05M | $546.29M | +9.2% |
| Goodwill & intangibles | $1.18B | $1.13B | $1.16B | $1.18B | $1.25B | +4.7% |
| Total assets | $3.78B | $3.54B | $3.68B | $3.60B | $3.42B | +6.7% |
| Total current liabilities | $883.19M | $728.05M | $881.63M | $862.11M | $1.11B | +21.3% |
| Current debt | $105.96M | $6.20M | $6.76M | $7.20M | $321.18M | +1,609.0% |
| Long-term debt | $2.56B | $2.57B | $2.57B | $2.57B | $2.15B | -0.0% |
| Total debt | $2.79B | $2.70B | $2.69B | $2.69B | $2.58B | +3.5% |
| Total liabilities | $3.74B | $3.59B | $3.75B | $3.71B | $3.54B | +4.4% |
| Retained earnings | -$415.09M | -$472.75M | -$535.00M | -$570.08M | -$572.45M | +12.2% |
| Shareholder equity | $33.02M | -$45.41M | -$70.79M | -$109.46M | -$112.12M | +172.7% |
| Working capital | $1.06B | $1.07B | $1.03B | $976.37M | $477.56M | -0.6% |
| Net tangible assets | -$1.15B | -$1.17B | -$1.23B | -$1.29B | -$1.36B | +2.2% |
| Shares issued | 319.33M | 319.00M | 314.56M | 314.31M | 314.04M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $69.61M | $78.00M | $49.57M | $18.13M | $35.61M | -10.8% |
| Depreciation & amortisation | $47.80M | $43.19M | $49.23M | $54.07M | $60.11M | +10.7% |
| Stock-based compensation | $10.39M | $8.82M | $8.20M | $8.22M | $8.27M | +17.9% |
| Change in working capital | -$191.51M | -$190.08M | -$12.29M | -$50.74M | -$35.11M | -0.8% |
| Operating cash flow | -$21.24M | -$26.74M | $130.31M | $118.45M | $83.82M | +20.6% |
| Capital expenditure | -$122.74M | -$21.71M | -$46.17M | -$22.46M | -$27.40M | -465.4% |
| Investing cash flow | -$122.74M | -$21.71M | -$45.45M | -$22.46M | -$26.55M | -465.4% |
| Financing cash flow | $79.36M | -$59.05M | -$10.12M | $59.44M | -$41.69M | +234.4% |
| Free cash flow | -$143.99M | -$48.45M | $84.15M | $95.99M | $56.42M | -197.2% |
| End cash position | $139.62M | $204.41M | $312.94M | $238.41M | $83.67M | -31.7% |
Options analytics
Put / call volume
0.15
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
17.50
-13.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
242
Contracts, this expiry
Put volume
37
Contracts, this expiry
Heaviest call OI
17.50
0 contracts
Heaviest put OI
17.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.23 | 0.30 | +30.3% |
| Mar 2026 | 0.17 | 0.27 | +59.6% |
| Dec 2025 | 0.18 | 0.21 | +14.1% |
| Sep 2025 | 0.14 | 0.17 | +22.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.23 | 7 | $812.11M | +3.5% |
| Next quarter | 0.22 | 7 | $824.78M | +1.3% |
| Current year | 1.02 | 7 | $3.16B | +4.5% |
| Next year | 1.19 | 7 | $3.44B | +9.1% |
Analyst targets & ownership
Mean target$22.71
High target$27.00
Low target$20.00
Implied upside11.92%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy3 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders52.10%
Held by institutions48.71%
Institutions holding425
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
20.08
+1.09% from price
SMA 20
19.02
+6.68% from price
SMA 50
18.41
+10.23% from price
SMA 100
16.97
+19.61% from price
SMA 200
15.09
+34.51% from price
EMA 12
19.82
+2.38% from price
EMA 26
19.13
+6.07% from price
EMA 50
18.42
+10.20% from price
RSI (14)
64.4
Neutral
MACD (12,26,9)
0.69
Hist 0.10
ATR (14)
0.91
4.47% of price
Realised vol 30D
41.5%
Annualised
Bollinger upper
21.71
20, 2σ
Bollinger lower
16.34
20, 2σ
50 / 200 cross
Golden
18.41 vs 15.09
Trend bias
Above 200
+34.51%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.63
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
41.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-22.3%
Peak to trough
Max drawdown 5Y
-78.3%
Peak to trough
ATR 14
0.91
4.47% of price
Beta (reported)
1.22
5Y monthly, from filing
Short interest
Shares short
11.29M
Prior 9.51M
Change vs prior
+18.7%
Shorts adding
% of float
4.60%
Normal
% of shares out
3.24%
Against total outstanding
Days to cover
7.2
Crowded exit
Float
197.33M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | Oppenheimer | INITIATED | — | Outperform |
| Sep 17, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 9, 26 | Leerink Partners | INITIATED | — | Outperform |
| Aug 3, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 15, 26 | UBS | MAINTAINED | Buy | Buy |
| May 20, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Apr 17, 26 | UBS | INITIATED | — | Buy |
| Mar 2, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Dec 9, 25 | Barclays | INITIATED | — | Overweight |
| Oct 31, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Sep 16, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Mar 3, 25 | Barclays | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-3ASR · 2026-09-03
Corporate Changes & Voting Matters
8-K · 2026-08-10
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-31
Corporate Changes & Voting Matters
8-K · 2026-07-30
Proxy Statements
DEFM14A · 2026-06-29
Proxy Statements
PREM14A · 2026-06-18
Headlines
3 Low-Volatility Stocks with Open Questions
StockStory · 2d ago
Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches
Simply Wall St. · 4d ago
Why Is Amneal (AMRX) Stock Rocketing Higher Today
StockStory · 15d ago
Ipsen Shares Fall After Early Launch of U.S. Generic Rival
The Wall Street Journal · 16d ago
Amneal Announces FDA Approval and Launch of Lanreotide Injection
GlobeNewswire · 19d ago
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
StockStory · 19d ago
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Zacks · 20d ago
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?
Simply Wall St. · 32d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.